DOP2022000159A - Moléculas de unión a antígeno y usos de las mismas - Google Patents

Moléculas de unión a antígeno y usos de las mismas

Info

Publication number
DOP2022000159A
DOP2022000159A DO2022000159A DO2022000159A DOP2022000159A DO P2022000159 A DOP2022000159 A DO P2022000159A DO 2022000159 A DO2022000159 A DO 2022000159A DO 2022000159 A DO2022000159 A DO 2022000159A DO P2022000159 A DOP2022000159 A DO P2022000159A
Authority
DO
Dominican Republic
Prior art keywords
antigen
binding molecules
relates
alppl2
methods
Prior art date
Application number
DO2022000159A
Other languages
English (en)
Spanish (es)
Inventor
Sun William
Wang Huajing
Leong Yap Thai
Yee Hong Shin
Wang Cheng-I
Huang Ching-Wen
Theng Lee Shuet
Fei Wan Kah
Duan Johnathan Ng Jian
Ooi Patrick Tan Boon
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of DOP2022000159A publication Critical patent/DOP2022000159A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DO2022000159A 2020-02-07 2022-08-05 Moléculas de unión a antígeno y usos de las mismas DOP2022000159A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10202001139U 2020-02-07
PCT/SG2021/050061 WO2021158178A1 (en) 2020-02-07 2021-02-05 Antigen-binding molecules against alppl2 and/or alpp and uses thereof

Publications (1)

Publication Number Publication Date
DOP2022000159A true DOP2022000159A (es) 2022-09-30

Family

ID=77199411

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2022000159A DOP2022000159A (es) 2020-02-07 2022-08-05 Moléculas de unión a antígeno y usos de las mismas
DO2025000135A DOP2025000135A (es) 2020-02-07 2025-06-06 Moléculas de unión a antígeno y usos de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
DO2025000135A DOP2025000135A (es) 2020-02-07 2025-06-06 Moléculas de unión a antígeno y usos de las mismas

Country Status (19)

Country Link
US (1) US20230080224A1 (cg-RX-API-DMAC7.html)
EP (1) EP4100443A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023512827A (cg-RX-API-DMAC7.html)
KR (1) KR20220139930A (cg-RX-API-DMAC7.html)
CN (1) CN115380050B (cg-RX-API-DMAC7.html)
AU (1) AU2021217919A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015540A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170141A1 (cg-RX-API-DMAC7.html)
CL (3) CL2022002114A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011944A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220441A (cg-RX-API-DMAC7.html)
DO (2) DOP2022000159A (cg-RX-API-DMAC7.html)
EC (1) ECSP22061867A (cg-RX-API-DMAC7.html)
IL (1) IL295291A (cg-RX-API-DMAC7.html)
JO (1) JOP20220175A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009709A (cg-RX-API-DMAC7.html)
PE (1) PE20221781A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552038A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021158178A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240083182A (ko) * 2021-09-22 2024-06-11 더 리전츠 오브 더 유니버시티 오브 캘리포니아 종양 특이적 이중특이성 면역세포 인게이저
CN120882866A (zh) * 2022-12-21 2025-10-31 阿尔麦克探索有限公司 Alpp特异性变体抗原结合分子
WO2026149352A1 (zh) * 2025-01-07 2026-07-16 北京泰德制药股份有限公司 一种抗alpp和/或alppl2抗体及其应用
WO2026156021A1 (en) 2025-01-16 2026-07-23 Merck Sharp & Dohme Llc Bispecific antibody constructs that bind alpp/alppl2 and cd3

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
KR20180005753A (ko) * 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Vegf를 억제하는 안정하고 가용성인 항체
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3383920B1 (en) * 2015-11-30 2024-01-10 The Regents of the University of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
JP2019131471A (ja) * 2016-05-27 2019-08-08 国立大学法人 東京大学 抗TGF−beta3抗体およびその使用
CN108088997B (zh) * 2016-11-21 2020-03-17 同济大学 利用细胞表面分子标志物鉴定人类原态多能性的方法

Also Published As

Publication number Publication date
CN115380050B (zh) 2026-07-03
AU2021217919A1 (en) 2022-09-29
PH12022552038A1 (en) 2023-11-29
BR112022015540A2 (pt) 2022-12-27
JP2023512827A (ja) 2023-03-29
CL2022002114A1 (es) 2023-03-03
ECSP22061867A (es) 2022-09-30
CL2024002074A1 (es) 2025-01-10
CR20220441A (es) 2022-12-14
JOP20220175A1 (ar) 2022-07-28
EP4100443A4 (en) 2024-05-15
IL295291A (en) 2022-10-01
CL2024002073A1 (es) 2025-01-10
KR20220139930A (ko) 2022-10-17
DOP2025000135A (es) 2025-07-15
CA3170141A1 (en) 2021-08-12
JP2026027248A (ja) 2026-02-18
CN115380050A (zh) 2022-11-22
US20230080224A1 (en) 2023-03-16
CO2022011944A2 (es) 2022-08-30
MX2022009709A (es) 2022-09-09
PE20221781A1 (es) 2022-11-16
WO2021158178A1 (en) 2021-08-12
EP4100443A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
DOP2025000135A (es) Moléculas de unión a antígeno y usos de las mismas
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
PE20210287A1 (es) Anti-cd25 para el agotamiento de celulas tumorales especificas
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
ECSP20084864A (es) Anticuerpos biespecíficos contra dll3-cd3
AR113862A1 (es) Anticuerpos anti-cd47 y sus usos para tratar cáncer
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
ECSP19021312A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos
CO2018004743A2 (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
CO2022015202A2 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
MX391279B (es) Anticuerpos biespecíficos contra cd3 y cd20.
MX2018010948A (es) INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
MX2021007104A (es) Inhibidores de kif18a.
MX2023001707A (es) Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
BR122021000898A8 (pt) Anticorpo anti-cd43 e uso do mesmo para tratamento de câncer
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2020008769A (es) Agentes anticuerpos anti-cd25.
MX2020013551A (es) Combinaciones farmaceuticas.
AR121696A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
CL2025002693A1 (es) Anticuerpos multiespecíficos anti-cd3 y métodos de uso.